Table 3.
Comparison of the antimicrobial resistance of Salmonella serovars from 2019–2020
| Antimicrobial agent | Number of resistant isolates (%) | ||
|---|---|---|---|
| S. Schwarzengrund n = 91 |
S. Manhattan n = 164 |
S. Infantis n = 13 |
|
| AMP | 0 (0.0) | 14 (8.5) | 0 (0.0) |
| CTX | 0 (0.0) | 13 (7.9) | 0 (0.0) |
| CFX | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| CTF | 0 (0.0) | 14 (8.5) | 0 (0.0) |
| OFLX | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| CP | 0 (0.0) | 1 (0.6) | 0 (0.0) |
| SM | 91 (100) | 159 (96.9) | 13(100) |
| SUL | 91 (100) | 138 (84.1) | 13(100) |
| OTC | 91 (100) | 108 (65.9) | 13(100) |
| KM | 75 (82.4) # | 0 (0) | 1 (7.7) |
AMP ampicillin, CTX cefotaxime, CFX cefoxitin, CTF ceftiofur, OFLX ofloxacin, CP chloramphenicol, SM streptomycin, SUL sulfamethoxazole, OTC oxytetracycline, KM kanamycin
# significantly greater proportion of kanamycin-resistant strains than other serovars (p < 0.05)